NCT00306904View on ClinicalTrials.gov

Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

December 31, 2007

Conditions
Diabetic Macular Edema
Interventions
DRUG

bevasiranib

Trial Locations (1)

44122

Retina Associates of Cleveland, Beechwood

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT00306904 - Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema | Biotech Hunter | Biotech Hunter